Rakovina Therapeutics

🌟 Rakovina Therapeutics is using AI to revolutionize cancer treatment by accelerating the discovery of new drug candidates targeting DNA-damage response inhibitors (DDRi). ⚡ With a projected market of US$18B by 2030, we are leading the charge in precision drug discovery, optimizing their approach by speeding up virtual screening by up to 100x. Learn more about our groundbreaking work in BNN Bloomberg's latest feature ⬇️ #Investing #TSXV #Stocks #CancerDrugs #Biopharma

💫 Don't miss our team at Invest in BC today and tomorrow! 🤝 We're excited to present and connect with #investors at this premier conference for life sciences innovators. Learn more about the event 👇 https://bit.ly/3zQPMwQ #RKV #LSBCInvest Life Sciences BC Lumira Ventures

🗓️ Rakovina Therapeutics is pleased to announce the presentation of our research on novel small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes today! Learn more about the results in our press release👇 https://bit.ly/4hi6NAZ #RKV #TSXV #Biopharma

🌟 Our Co-founder & Chairman, Jeffrey Bacha, and President & CSO, Dr. Mads Daugaard, will be at Invest in BC! 🗓️ Interested in discussing our latest advancements? Reach out to ir@rakovinatherapeutics.com to request a meeting. #RKV #LSBCInvest Life Sciences BC Lumira Ventures

💡 Check out our Q&A on Techcouver! 💭 Our Co-founder & Executive Chairman, Jeffrey Bacha discusses how we are leveraging our Deep-Docking™ AI Platform to accelerate drug discovery, targeting DNA-damage response mechanisms that are key in many cancers. 🌟 This approach aims to develop breakthrough therapies that could change the future for cancer patients. Read the full interview to learn more ⬇️ #Investing #CancerDrugs #Biopharma #Stocks #TSXV

🎙️ Did you miss this interview? 💬 Our President & Chief Scientific Officer, Dr. Mads Daugaard, recently shared his thoughts on the future of cancer treatment, stating that there is no silver bullet for cancer. He emphasized the need for multiple shots on goal—using a combination of therapies to manage cancer as tumors constantly evolve. 🔬 At Rakovina Therapeutics, we are leading the charge in developing next-generation DNA damage response inhibitors, combining cutting-edge AI to revolutionize treatment. Read the full interview ⬇️ #Investing #TSXV #Stocks #CancerDrugs #Biopharma

👋 Meet the team behind #RakovinaTherapeutics! 🌟 Our President & Chief Scientific Officer, Dr. Mads Daugaard is a recognized world-leader in the field of translational #CancerResearch with strong expertise in DNA-damage response. 🔬 His research has been published in top-tier peer-reviewed scientific journals. He has previously co-founded the cancer therapeutics company VAR2 Pharmaceuticals and the cancer diagnostic company VarCT Diagnostics, and served as CSO for VAR2 Pharmaceuticals from 2012 to 2016. Take a look at his explainer videos to learn more about us ⬇️ https://bit.ly/4gjFSnT #Investing #TSXV #Biopharma

Did you miss it? Our co-founder & Executive Chairman, Jeffrey Bacha, was featured in a BNN Bloomberg article! Read the full article to learn how we are using AI to accelerate cancer drug discovery👇 https://bit.ly/4gKOowp #RKV #Investing #TSXV #Stocks #CancerDrugs #Biopharma

If you missed our recent webinar with Radius Research, you can watch it here.

🌟 The #biopharma industry is embracing AI, with major companies like Gilead Sciences investing $35M in a collaboration with Genesis Therapeutics to harness its GEMS AI platform for drug discovery. At Rakovina Therapeutics, we are excited to see AI take biopharma R&D to new heights. Read the news here 👇 #Investing #TSXV #Stocks